Indications for: FERRLECIT
Iron deficiency anemia in patients with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.
Give by IV infusion (diluted) or slow IV inj (undiluted). 125mg infused over 1 hour or by slow IV inj (at a rate of up to 12.5mg/min). Minimum cumulative dose: 1g given over 8 sequential dialysis sessions; usual max: 125mg/dose.
<6yrs: not established. Give by IV infusion (diluted) over 1 hour. ≥6yrs: 1.5mg/kg per dose at 8 sequential dialysis sessions; max: 125mg/dose.
Risk of serious hypersensitivity reactions; monitor during and after administration for ≥30mins. Have personnel and resuscitative equipment readily available. Iron overload. Periodically monitor hematologic and iron parameters, and BP during and after administration. Elderly. Neonates/infants: risk of serious adverse reactions due to benzyl alcohol. Pregnancy, nursing mothers: consider alternative therapies without benzyl alcohol.
May reduce absorption of concomitant oral iron preparations.
Nausea, vomiting, diarrhea, inj site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps, and pain; in children: also headache, tachycardia; hypersensitivity reactions.
Single-dose vials (5mL)—10